Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Obesity & Overweight, Prediabetes
Interventions: Precision Nutrition Intervention, Standard Nutrition Counseling; Behavioral
Lead sponsor: Prairie View A&M University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Prairie View, Texas

Conditions: Type 2 Diabetes Mellitus (T2DM), Pregnancy
Interventions: CGM; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina + 4 more

Conditions: Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study; Biological · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Voorhees Township, New Jersey • Dallas, Texas • Houston, Texas + 3 more

Conditions: Alzheimer Disease, Diabetes Mellitus, Type 2
Interventions: Tailored Lighting Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Albany, New York • New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: JTT-662, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer
Interventions: Group pre-operative counseling; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: pioglitazone, Placebo control; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Diabetes
Interventions: Sleep extension, Fixed Sleep Duration; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 10 Years to 16 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Type 2 Diabetes
Interventions: Lysulin; Dietary Supplement
Lead sponsor: Juraj Koska; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Diabetes, Hypoglycemia
Interventions: hyperinsulinemic-hypoglycemic clamp, 13C-MRS procedure/Acetate infusion; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Metformin, GLP-1A, MED; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: dutogliptin; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 27
States / cities: Fullerton, California • Long Beach, California • Orange, California + 24 more

Conditions: Acute Myocardial Infraction or Chest Pain, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Diabetes, Pneumonia
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Hepatic Ultrasound Insonification; Device
Lead sponsor: General Electric Research; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions: Pioglitazone, Exercise Training; Drug · Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 28 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 1 Diabetes
Interventions: Fit Families plus Standard Medical Care; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Gestational Diabetes, Pre-Eclampsia, Blood Pressure
Interventions: LabClasp; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: CTLA-4 Ig, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: DDR, Treadmill; Behavioral
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bioavailability, Bioequivalence
Interventions: TEPEZZA, EDP; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Type II
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 21 Years
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions: Observational Cohort; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Risk Pregnancy, Remote Patient Monitoring, Diabetes, Hypertension
Interventions: Fetal ECG monitoring; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Precision Nutrition for Obesity and Prediabetes Prevention in Under-supported Communities

CGM for Management of Type 2 Diabetes in Pregnancy

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Light and the Effect on Metabolic Syndrome and Alzheimer's Disease

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Effects of Centering Pre-operative Counseling on Patient Reported Anxiety

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

Sleep Intervention for Youth With Type 1 Diabetes

The Effect of Lysulin on Glycemic Control and Advanced Glycation

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Developing Enhanced Prediction Models

Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

Home-Based Interventions for Adolescents With Type 1 Diabetes

Glucose and Blood Pressure During Pregnancy

Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus

Dance Dance Revolution (DDR) in Type 2 Diabetes

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

Novel Biomarker for Development of T2D

Predicting Disease Progression and/or Recurrence in Cancer

Remote Fetal Monitoring in High Risk Pregnancies